From Benzinga's Cannabis Capital Conference: PharmaCann CEO Brett Novey Says We're Growing; In Seven States; Gummies And Vapes Winning Awards; Go To States And Collect Rewards And Build Reputation; In 3-4-5 Years From Now Aim To Be Number One
Portfolio Pulse from Benzinga Newsdesk
At Benzinga's Cannabis Capital Conference, PharmaCann CEO Brett Novey discussed the company's growth across seven states, highlighting their award-winning gummies and vapes. Novey emphasized the strategy of entering new states to collect rewards and build reputation, with the goal of becoming the number one cannabis company in 3-4-5 years.
April 17, 2024 | 3:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MSOS, an ETF that includes U.S. cannabis companies, may see a positive impact from PharmaCann's growth and strategic market expansion as highlighted by CEO Brett Novey.
PharmaCann's strategic expansion and success in product development could indicate a strengthening U.S. cannabis market. As MSOS includes companies like PharmaCann, its performance and reputation growth could positively influence the ETF's value.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70